Compare iShares 3 7 Year Treasury Bond ETF (IEI) vs Medtronic PLC (MDT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 3 7 Year Treasury Bond ETF vs Medtronic PLC — how do they compare? iShares 3 7 Year Treasury Bond ETF trades at $116.48, while Medtronic PLC trades at $90.73 (market cap $116.07B). The key difference: Medtronic PLC pays a 3.18% dividend while iShares 3 7 Year Treasury Bond ETF pays none, and Medtronic PLC is trading nearer its 52-week high, iShares 3 7 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| IEI | MDT | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $120.72 | $105.35 |
52-Week Low | $116.16 | $73.75 |
Market Cap | — | $116.07B |
Enterprise Value | — | $134.82B |
Dividend Yield | — | 3.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEI, the iShares 3-7 Year Treasury Bond ETF, trades at $116.46, up 0.18% on the day, amid a bearish technical signal from moving averages and neutral oscillators. The ETF maintains a steady dividend payout schedule, with recent distributions around $0.37 per share. Market sentiment is influenced by rising Treasury yields and inflation concerns, as highlighted in recent financial news.
The outlook for IEI is cautious due to potential Federal Reserve rate hikes and inflation pressures, which could pressure bond prices. Opportunities lie in its government backing and lower volatility, but risks include interest rate sensitivity and macroeconomic shifts affecting yield curves.
Medtronic (MDT) trades at $90.70, up 1.44% with strong technical momentum and bullish moving average signals. The company demonstrates solid fundamentals with consistent earnings beats, including Q1 2026 EPS of $1.55 beating expectations of $1.54. Revenue growth accelerated to $33.54 billion in 2025 with improving profit margins of 13.2%. Recent positive developments include new product approvals and institutional accumulation, though RSI levels suggest potential near-term overbought conditions.
The outlook remains positive with analyst consensus targeting $98.75 (8.9% upside) and no sell ratings. Key opportunities include robotic surgery platform expansion and cardiac ablation growth, while risks involve rising debt levels and competitive pressures. The stock offers dividend stability with a $0.72 upcoming payment, making it attractive for income-focused investors seeking medical technology exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares 3 7 Year Treasury Bond ETF
IEI tracks the ICE U.S. Treasury 3-7 Year Bond Index, offering exposure to intermediate-term government debt. It serves as a conservative middle ground in the Treasury yield curve, providing higher yields than short-term bills with less volatility than long-term bonds.
Read more on IEI →About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →
